Moderna Inc. (MRNA)
MRNA trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price · October 14, 2026
$216.25
+1.17% on the day
Market cap
$86.3B
Large cap
Revenue · 2025
$1.9B
-39.9% on 2024
Net income · 2025
-$2.8B
-145.2% net margin
Price, change, market cap, sector and industry: Nasdaq stock screener, as of October 14, 2026. Revenue: SEC XBRL frames, calendar 2025.
Profile
| Field | Value |
|---|---|
| Ticker | MRNA on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Country | United States |
| IPO year | 2018 |
| SEC CIK | 0001682852 |
| SEC industry code | Biological Products, (No Diagnostic Substances) |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $1.9B |
| Net income | -$2.8B |
| Operating income | -$3.1B |
| Net margin | -145.2% |
| Operating margin | -158.1% |
| Revenue growth | -39.9% |
| Cash | $2.6B |
| Total assets | $12.3B |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 44.4× |
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | S-3ASR | 2023-05-05 |
| Latest annual report | 10-K | 2026-02-20 |
| Latest quarterly / interim | 10-Q | 2026-07-31 |
| Latest current report | 8-K | 2026-09-30 |
| Latest proxy DEFINITIVE ADDITIONAL PROXY SOLICITING MATERIALS | DEFA14A | 2026-03-16 |
Source: SEC EDGAR submissions feed, 1,001 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +14.6% |
| 1 month | +56.6% |
| 3 months | +256.6% |
| Year to date | +663.6% |
| 1 year | +742.1% |
| From 52-week high | 0.0% |
Source: Yahoo Finance daily closes, last bar 2026-10-14. Computed by Sophia Capital from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Biological Products (No Diagnostic Substances)
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| ARGX | argenx SE | $802.64 | -1.19% | $49.8B |
| GILD | Gilead Sciences Inc. | $147.92 | -1.67% | $183.4B |
| RVMD | Revolution Medicines Inc. | $188.44 | -2.84% | $40.4B |
| BIIB | Biogen Inc. | $228.90 | -0.22% | $33.8B |
| AMGN | Amgen Inc. | $412.84 | -1.13% | $223.2B |
| BNTX | BioNTech SE American Depositary Share | $89.01 | -7.13% | $22.4B |
| EXEL | Exelixis Inc. | $59.51 | -0.52% | $14.7B |
| NBIX | Neurocrine Biosciences Inc. | $135.13 | -4.41% | $13.7B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier